Combination approaches to combat multidrug-resistant bacteria
TLDR
Recent developments toward combination therapies for the treatment of multidrug-resistant bacterial infections are described, and the development of adjuvants that either directly target resistance mechanisms such as the inhibition of β-lactamase enzymes, or indirectly target resistance by interfering with bacterial signaling pathways such as two-component systems (TCSs).About:
This article is published in Trends in Biotechnology.The article was published on 2013-03-01 and is currently open access. It has received 459 citations till now. The article focuses on the topics: Antibiotic resistance.read more
Citations
More filters
Journal ArticleDOI
Phage Therapy in the Postantibiotic Era
TL;DR: The benefits of phage therapy beyond the clinical perspective are discussed, including opportunities for scientific outreach and effective education, interdisciplinary collaboration, cultural and economic growth, and even innovative use of social media, making the case thatphage therapy is more than just an alternative to antibiotics.
Journal ArticleDOI
Drug combinations: a strategy to extend the life of antibiotics in the 21st century.
Mike Tyers,Gerard D. Wright +1 more
TL;DR: A theoretical and practical framework for the development of effective antibiotic combinations is outlined and a productive strategy to address the widespread emergence of antibiotic-resistant strains is proposed.
Journal ArticleDOI
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
TL;DR: Adjuvants offer a means to both suppress the emergence of resistance and rescue the activity of existing drugs, offering an orthogonal strategy complimentary to new antibiotic discovery VIDEO ABSTRACT.
Journal ArticleDOI
Droplet microfluidics for microbiology: techniques, applications and challenges
TL;DR: Applications of droplet microfluidics in various fields of microbiology are presented: i) detection and identification of pathogens, ii) antibiotic susceptibility testing, iii) studies of microbial physiology and iv) biotechnological selection and improvement of strains.
Journal ArticleDOI
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning.
Kristina Preuer,Richard J. Lewis,Sepp Hochreiter,Andreas Bender,Krishna C. Bulusu,Krishna C. Bulusu,Günter Klambauer +6 more
TL;DR: DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies and could be a valuable tool for selecting novel synergistic drug combinations.
References
More filters
Journal ArticleDOI
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
Brad Spellberg,Robert Guidos,David N. Gilbert,John S. Bradley,John S. Bradley,Helen W. Boucher,W. Michael Scheld,John G. Bartlett,John E. Edwards +8 more
TL;DR: If the antimicrobial resistance crisis is to be addressed, a concerted, grassroots effort led by the medical community will be required and could mean a literal return to the preantibiotic era for many types of infections.
Journal ArticleDOI
Molecular mechanisms that confer antibacterial drug resistance
TL;DR: The authors live in an era when antibiotic resistance has spread at an alarming rate and dire predictions concerning the lack of effective antibacterial drugs occur with increasing frequency, so it is apposite to ask a few simple questions about these life-saving molecules.
Journal ArticleDOI
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Laurent Poirel,Patrice Nordmann +1 more
TL;DR: In addition to beta-lactamases, carbapenem resistance in A. baumannii may also result from porin or penicillin-binding protein modifications, and several porins, including the 33-kDa CarO protein, that constitute a pore channel for influx ofcarbapenems, might be involved in carbapanem resistance.
Journal ArticleDOI
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005.
TL;DR: MRSA should be a national priority for disease control, according to the World Health Organization.
Journal ArticleDOI
New uses for old drugs
TL;DR: It takes too long and costs too much to bring new drugs to market, so let's beef up efforts to screen existing drugs for new uses, argue Curtis R. Chong and David J. Sullivan Jr.
Related Papers (5)
Antibiotic resistance—the need for global solutions
Ramanan Laxminarayan,Ramanan Laxminarayan,Ramanan Laxminarayan,Adriano Duse,Chand Wattal,Anita K. M. Zaidi,Heiman F. L. Wertheim,Nithima Sumpradit,Erika Vlieghe,Gabriel Levy Hara,Ian M. Gould,Herman Goossens,Christina Greko,Anthony D. So,Maryam Bigdeli,Goeran Tomson,Will Woodhouse,Eva Ombaka,Arturo Quizhpe Peralta,Farah Naz Qamar,Fatima Mir,Sam Kariuki,Zulfigar A. Bhutta,Anthony R.M. Coates,Richard Bergstrom,Gerard D. Wright,Eric D. Brown,Otto Cars +27 more